The Vitro Study Of Enhancement On The Chemotherapy Sensitivity Of The Prostate Cancer22RV1Celline By The GSK-3β Inhibitor

Objective:To study the mechanism of enhancement on the chemotherapy sensitivity of the prostate cancer22RV1cell by the GSK-3β inhibitor in vitro.Methods:1. We evaluated the toxicity of DTX combined with GSK-3β inhibitor LiCl on the prostate cancer cell line-22RV1cell by crystal violet staining.2. We used the Western Blot method to study the effect of. GSK-3βactivity on the autophagy level induced by DTX.3. We adopted the immunoprecipitation method to monitor the regulation on the combination of autophagy complex with downstream molecules by GSK-3β inhibitor LiCl.Results:On the basis of DTX, GSK-3β inhibitor LiCl can decrease the activity of GSK-3β; increase the expression of ATG14L, Beclin-1and decrease the expression of Rubicon; increase the combination of beclin-1with ATG14L; decrease the combination of beclin-1with Rubicon. Therefore, the autophagy level of the prostate cancer was up-regulated and driven to autophagic cell death.Conclusions:GSK-3β inhibitor LiCl can increase the autophagy level of the prostate cancer induced by DTX and enhance the chemotherapy effect.